HDAC9 and triple-negative breast carcinoma: To address the question of whether AIM genes are re-expressed in vivo, we queried RNA from patients with triple negative breast cancer [26] and colorectal cancer receiving combination epigenetic therapy with AZA and an HDAC inhibitor, entinostat, with the AIM panel.